Venus Remedies Clinches WHO-Backed PAHO tender, takes its global fight against Cancer to next level

Venus Remedies has announced that in a development crucial to improving healthcare outcomes in Latin America, leading pharmaceutical company Venus has been awarded an oncology tender by the WHO-backed Pan American Health Organisation (PAHO), the world's oldest international public health agency, for supplying essential cancer drugs to multiple Latin American countries. This achievement signifies a major milestone for Venus Remedies, enhancing its contribution to global health initiatives and reinforcing its commitment to improving global health outcomes by providing life-saving medicines to those who need them the most. The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs like bleomycin, carboplatin, cisplatin, cytarabine, doxorubicin, irinotecan, methotrexate, and vincristine. This prestigious tender award highlights Venus Remedies' commitment to advancing healthcare and its crucial role in the global battle against cancer.

Shares of Venus Remedies Limited was last trading in BSE at Rs. 378.25 as compared to the previous close of Rs. 375.05. The total number of shares traded during the day was 12248 in over 681 trades.

The stock hit an intraday high of Rs. 382.90 and intraday low of 376.65. The net turnover during the day was Rs. 4638898.00.

Source : Equity Bulls

Keywords

VenusRemedies INE411B01019 OrderWin WHO PAHOtender Cancer